Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus versus Advagraf in de novo liver transplant recipients
2024-518033-28-00Phase 4Completed
- Sponsor
- Regensburg University Medical Center
- Start
- Nov 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in graft rejection (2 arms), sponsored by Regensburg University Medical Center. Primary endpoint: Dose-normalized trough level at 12 weeks. Started Nov 2020; status: completed.
02
Drugs
tacrolimus
03
Conditions
graft rejection
Beyond the preview
Go deeper on 2024-518033-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518033-28-00.